$0.23
0.00 (-1.11%)
Open$0.23
Previous Close$0.23
Day High$0.24
Day Low$0.23
52W High$1.55
52W Low$0.51
Volume—
Avg Volume216.8K
Market Cap42.59M
P/E Ratio—
EPS$-0.68
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+8,677.1% upside
Current
$0.23
$0.23
Target
$20.24
$20.24
$11.64
$20.24 avg
$22.20
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 7.82M | 7.64M | 6.13M |
| Net Income | -1,043,017 | -954,590 | -792,337 |
| Profit Margin | -13.3% | -12.5% | -12.9% |
| EBITDA | -1,028,959 | -906,364 | -702,614 |
| Free Cash Flow | -801,636 | -705,541 | -523,657 |
| Rev Growth | -3.5% | +15.6% | +20.8% |
| Debt/Equity | 1.41 | 1.39 | 1.07 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |